English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

In the paper by Charest et al. [1] published in this issue of the European Journal of Nuclear Medicine and Molecular Imaging, the sensitivity of FDG PET/CT in detecting sarcoma lesions turned out to be very high (80 to 100% according to the histological type of disease). This result, obtained retrospectively on a large series of 212 patients, is concordant to what is reported in the recent literature and suggests one should consider this imaging method in the routine diagnostic work up of patients affected by sarcomas for staging and restaging the disease. Interestingly, FDG PET/CT had a high sensitivity both for bone and soft-tissue sarcoma and only ten false-negative cases were recorded. Some of these false-negatives were caused by the small diameter of the lesions and the remaining ones were related to the SUVmax cut-off value chosen to discriminate between malignant and benign lesions (2.5). Probably the latter ones could have been avoided in the clinical practice taking into consideration also visual criteria and not only SUV parameters. According to the literature, besides staging and restaging, FDG PET/CT could also play an important role for assessing the patient prognosis and the response to chemotherapy.

Positron emission tomography for the evaluation of soft-tissue sarcomas and bone sarcomas